Overview: Carboplatin is used to treat certain types of cancer. Common side effects include hair loss, low blood cell counts, nausea, and vomiting. You may also get numbness, tingling, burning, or ...

Adjusted HR (95% CI) of PFS for intraperitoneal (IP) carboplatin vs. intravenous (IV) carboplatin = 0.92 (0.75 – 1.13). Adjusted HR (95% CI) of PFS for IP cisplatin vs. IV carboplatin = 0.97 (0.79 – 1 ...

Carboplatin is given as an intravenous infusion over half an hour to 1 hour, which is usually performed as a day care procedure or during a short stay at hospital.

Carboplatin is used to treat ovarian cancer in adults. Find out about cost, financial assistance, and more. ... (IV) infusion from a healthcare professional in a hospital or clinic.

Markman, M, Bundy, BN, Alberts, DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and ...

Additionally, median overall survival (time from treatment until death by any cause) across the three groups was 106.6 months for intravenous carboplatin, 114.2 months for intraperitoneal carboplatin ...

However, there was no benefit in overall survival (OS) with IP carboplatin, with a median OS of 64.9 months versus 67 months in the IV arm in the ITT population (HR 0.95, 95% CI 0.77-1.17, P=0.041 ...

After surgery, patients in the intravenous (IV) arm of the study (arm 1; 101 patients) were treated with IV paclitaxel (135 mg/m2) and IV carboplatin (AUC 5/6) on day one, followed by IV paclitaxel ...

Interest in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer with minimal residual disease following initial cytoreductive surgery has been rekindled with the recent ...

The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III ...